Program
Main Content
All events will take place at the Nittany Lion Inn unless otherwise noted. Additional details will be updated as planning progresses. Please check back!
Download PDF of Program here.
Sunday, July 22, 2012
Registration Check-In
11:00 a.m. - 1:15 p.m., Rotunda, Main Floor
Coffee & Tea Welcome Reception,
12:00 - 1:15 p.m., Ground Floor Lobby, outside of Boardroom
Opening Remarks
1:15 - 4:30 p.m., Boardroom, Ground Floor
CAR / PXR
Oral Presentations I
1:30 - 2:00 p.m.
Structural Biology of Xenobiotics Receptor CAR
and Other Nuclear Receptors
H. Eric Xu, VARI/SIMM Research Center
2:00 - 2:30 p.m.
In Vitro Identification of Novel CAR Activators:
Integration of Computational and Biological Approaches
Hongbing Wang, University of Maryland
2:30-3:00 p.m.
Natural Splice Variation in Human CAR Specifies Receptors
With Unique Biological Properties
Curt Omiecinski, Penn State University
3:00 - 3:30 p.m.
Regulation of Drug Transporters by Nuclear Receptors in the Brain
Reina Bendayan, University of Toronto
3:30 - 4:00 p.m.
Role of PXR in Malignancy
Sridhar Mani, Albert Einstein College of Medicine
4:00 - 4:30 p.m
The Endobiotic Function of CAR and PXR in Energy Metabolism
Wen Xie, University of Pittsburgh
Reception
4:30 - 6:00 p.m., Patio, Main Floor
Dinner
6:00 - 7:30 p.m., Ballroom, Main Floor
Plenary Address
7:30 - 8:30 p.m., Boardroom, Ground Floor
Transcription Dynamics, Chromatin Transitions,
and the Mechanism of Regulatory Element Function
Gordon Hager, National Cancer Institute, NIH
Monday, July 23, 2012
Keynote Address
8:00 - 9:00 a.m., Boardroom, Ground Floor
Incorporating Our Evolving Understanding of Nuclear Receptor Action
Into Mechanism-Based Screens for Endocrine Disrupters
Donald P. McDonnell, Duke University Medical School
PPAR
Oral Presentations II
9:15 - 10:45 a.m., Boardroom, Ground Floor
9:15 - 9:45 a.m.
Genome-Wide Approaches to Understanding Nuclear Receptor Function
Christopher K. Glass, University of California, San Diego
9:45 - 10:15 a.m.
Role of PPARa in Chemical Toxicity and Carcinogenesis
Frank Gonzalez, National Cancer Institute, NIH
10:15 - 10:45 a.m.
Mechanism of Action of Novel Insulin Sensitizers
Patrick R. Griffin, The Scripps Research Institute
Poster Exhibits / Refreshments
10:45 a.m. - 12:00 p.m., Faculty / Staff Club, Ground Floor
Luncheon / Free Time
12:00 - 1:30 p.m.
PPAR
Oral Presentations III
1:30 - 3:00 p.m., Boardroom, Ground Floor
1:30 - 2:00 p.m.
PPARβ/δ, A Modulator of Cytokine Signaling and Tumorigenesis
Rolf Müller, Philipps University, Germany
2:00 - 2:30 p.m.
Peroxisome Proliferator-Activated Receptor-β/δ-Dependent Regulation of Cancer
Jeff Peters, Penn State University
2:30 - 3:00 p.m.
Bart Staels, University of Lille Nord de France
Coffee / Tea Refreshments
3:00 - 3:30 p.m., Ground Floor Lobby outside of Boardroom
Ah Receptor, Oral Presentations IV
3:30 - 5:00 p.m., Boardroom, Ground Floor
3:30 - 4:00 p.m.
Development and Therapeutic Potential of Selective Ah Receptor Modulators
Gary H. Perdew, Penn State University
4:00 - 4:30 p.m.
Control of Human Hematopoietic Stem Cell Self-Renewal and
Differentiation by the Aryl Hydrocarbon Receptor
Michael P. Cooke, Genomics Institute of the Novartis Research Foundation
4:30 - 5:00 p.m.
AhR and the Immune Cells of Barrier Organs
Charlotte Esser, Institut für Umweltmedizinische Forschunt (IUF), Germany
Reception
5:30 - 7:00 p.m., The Arboretum at Penn State Pavilion
Dinner
7:00 - 8:30 p.m., Patio
Tuesday, July 24, 2012
Ah Receptor, Oral Presentations V
8:00 - 9:30 a.m., Boardroom, Ground Floor
8:00 - 8:30 a.m.
Biological Properties of the High Affinity Endogenous Aryl
Hydrocarbon Receptor Ligand FICZ
Agneta Rannug, Karolinska Institute, Sweden
8:30 - 9:00 a.m.
Dioxin, Clocks and Oxygen
Christopher Bradfield, University of Wisconsin
9:00 - 9:30 a.m.
The Aryl Hydrocarbon Receptor as a Drug Target
for Treating Advanced Breast Cancer
Stephen Safe, Texas A & M University
Poster Exhibits / Refreshments
9:30 - 10:30 a.m., Faculty / Staff Club, Ground Floor
Applications / Biological Utility of Receptor Technologies,
Oral Presentations VI
10:30 a.m. - 1:00 p.m., Boardroom, Ground Floor
10:30 - 11:00 a.m.
Early Safety Assessment - When Chemistry Meets Biology
Craig E. Thomas, Eli Lilly and Company
11:00 - 11:30 a.m.
Nuclear Receptor Activity Across Chemical Classes:
Comparing ER and AhR Activity Trends Between Environmental Chemicals
and Pharmaceuticals and Reference Compounds
Richard Judson, National Center for Computational Toxicology
11:30 a.m. - 12:00 p.m.
The AH Receptor: Species Studies, Mode-of-Action,
and Implication for Human Risk Assessment
J. Craig Rowlands, The Dow Chemical Company
12:00 - 12:30 p.m.
Cryopreserved HepaRG Cells™ as Alternatives to Primary
Human Hepatocytes for Modeling Receptor Activation Phenotypes
Stephen Ferguson, Life Technologies, Inc.
12:30 - 1:00 p.m.
Nuclear Receptors as Nutritional Targets:
Implications for Prevention and Treatment of Metabolic Syndrome
Jack Vanden Heuvel, Penn State University
Summary Remarks
1:00 - 1:30 p.m., Boardroom, Ground Floor
Meeting Adjourned
1:30 p.m.
Updated 5/10/2012

